Vaughn Christopher, Zhang Louann, Schiff David
Division of Hematology/Oncology, University of Virginia Health System, PO Box 800716, Charlottesville, VA 22908, USA.
Curr Oncol Rep. 2008 Jan;10(1):86-91. doi: 10.1007/s11912-008-0013-z.
Reversible posterior leukoencephalopathy syndrome (RPLS) is a subacute neurological syndrome typically manifesting with headache, cortical blindness, and seizures. The syndrome is associated with risk factors such as malignant hypertension, eclampsia, and renal failure. Numerous case reports depict its occurrence in cancer patients. The direct causal relationship for the mechanism of RPLS in cancer patients has not yet been defined. Cytotoxic chemotherapy may cause direct endothelium damage, which would impact the blood-brain barrier. Chemotherapies also cause elevations in blood pressure; this is significant because RPLS onset may be solely related to hypertension. An increased number of case reports involving new targeted agents suggests that RPLS incidence may increase in the future. Agents such as bevacizumab and sorafenib have been implicated in new cases of RPLS.
可逆性后部白质脑病综合征（RPLS）是一种亚急性神经综合征，通常表现为头痛、皮质盲和癫痫发作。该综合征与恶性高血压、子痫和肾衰竭等危险因素有关。大量病例报告描述了其在癌症患者中的发生情况。RPLS在癌症患者中的发病机制尚未明确。细胞毒性化疗可能导致直接的内皮损伤，从而影响血脑屏障。化疗还会导致血压升高；这一点很重要，因为RPLS的发病可能仅与高血压有关。越来越多涉及新型靶向药物的病例报告表明，RPLS的发病率未来可能会增加。贝伐单抗和索拉非尼等药物已被牵涉到RPLS的新病例中。
